Trials / Recruiting
RecruitingNCT06503237
Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-CD19 CART cells will be given IV at split doses. | Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg). |
Timeline
- Start date
- 2023-11-09
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2024-07-16
- Last updated
- 2025-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06503237. Inclusion in this directory is not an endorsement.